EUVIMEDEUVIMED entdecken
Crossref

Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019

Gordon Chun Kau Chan, Grace Chung Yan Lui, Candy Ngai Sze Wong, Sindy Sin Ting Yip, Timothy Chun Man Li, Catherine Siu King Cheung, Ryan Kin Ho Sze, Cheuk Chun Szeto, Kai Ming Chow iD

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Gordon Chun Kau Chan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region (SAR)…. Hauptthemen laut MEDLINE: COVID-19, Renal Insufficiency, Chronic, Kidney Failure, Chronic, Lactams. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Charlie Lee Charitable Foundation, Baxter Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nirmatrelvir-ritonavir is currently not recommended in patients with an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2.

Methods

To determine the safety profile and clinical and virological outcomes of nirmatrelvir-ritonavir use at a modified dosage in adults with chronic kidney disease (CKD), a prospective, single-arm, interventional trial recruited patients with eGFR <30 mL/minute/1.73 m2 and on dialysis. Primary outcomes included safety profile, adverse/serious adverse events, and events leading to drug discontinuation. Disease symptoms, virological outcomes by serial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral polymerase chain reaction (PCR) tests, rapid antigen tests, and virological and symptomatic rebound were also recorded.

Results

Fifty-nine (69.4%) of the 85 participants had stage 5 CKD and were on dialysis. Eighty (94.1%) completed the full treatment course; 9.4% and 5.9% had adverse and serious adverse events, and these were comparable between those with eGFR < or >30 mL/minute/1.73 m2. The viral load significantly decreased on days 5, 15, and 30 (P < .001 for all), and the reduction was consistent in the subgroup with eGFR <30 mL/minute/1.73 m2. Ten patients had virological rebound, which was transient and asymptomatic.

Conclusions

Among patients with CKD, a modified dose of nirmatrelvir-ritonavir is a well-tolerated therapy in mild COVID-19 as it can effectively suppress the SARS-CoV-2 viral load with a favorable safety profile. Virological and symptomatic rebound, although transient with low infectivity, may occur after treatment. Nirmatrelvir-ritonavir should be considered for use in patients with CKD, including stage 5 CKD on dialysis. Clinical Trials Registration. Clinical Trials.gov; identifier: NCT05624840.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Renal Insufficiency, ChronicKidney Failure, ChronicLactamsLeucineNitrilesProlineAdultHumansSARS-CoV-2Prospective StudiesRitonavirCOVID-19 Drug TreatmentAntiviral Agents

Stichwörter der Autor:innen

chronic kidney diseasedialysisnirmatrelvir-ritonavirrebound

Substanzen

nirmatrelvirRitonavirAntiviral AgentsLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.
  • The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Microbiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Kai Ming Chow

Förderung

  • Charlie Lee Charitable Foundation
  • Baxter Healthcare

Zitieren

APA

Chan, G. C. K., Lui, G. C. Y., Wong, C. N. S., Yip, S. S. T., Li, T. C. M., Cheung, C. S. K., Sze, R. K. H., Szeto, C. C., & Chow, K. M. (2023). Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad371

Vancouver

Chan GCK, Lui GCY, Wong CNS, Yip SST, Li TCM, Cheung CSK, et al. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad371

BibTeX
@article{Chan2023,
  author = {Chan, Gordon Chun Kau and Lui, Grace Chung Yan and Wong, Candy Ngai Sze and Yip, Sindy Sin Ting and Li, Timothy Chun Man and Cheung, Catherine Siu King and Sze, Ryan Kin Ho and Szeto, Cheuk Chun and Chow, Kai Ming},
  title = {Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad371}
}
Kostenlos starten →